GBS Global Biopharma

GBS Global Biopharma is a clinical-stage biotechnology company specializing in the development of cannabinoid-based therapeutic products. Operating as a subsidiary of Intelligent Bio Solutions Inc. (formerly GBS Inc.), the company focuses on utilizing the medicinal properties of cannabis to treat complex conditions such as COVID-19 and neuropathic pain. Their research is centered on the endocannabinoid system, specifically targeting CB1 and CB2 receptors to modulate immune responses and pain signaling. GBS Global Biopharma maintains a library of proprietary cannabinoid formulations designed for specific clinical indications. The company's mission is to provide evidence-based cannabinoid treatments as alternatives to conventional therapies.